… the optimal dose of dabigatran for Korean patients with AF. … dabigatran 110 mg is the optimal
dose for Korean patients with … patients being treated with guideline-concordant dabigatran …

… We prospectively enrolled the patients prescribed with dabigatran in 10 tertiary hospitals
of the South Korea. The adherence was assessed using the percentage of the prescribed …

… values than rivaroxaban and dabigatran in our study… Korean patients with AF showing
excellent results in both the effectiveness and safety of these two NOACs in the primary prevention …

… Subgroup analysis showed greater benefits in the prevention of ischemic stroke with
dabigatran than with warfarin in the elderly, but there was no significant benefit over warfarin for …

… All the patients in this study received either dabigatran or rivaroxaban for stroke prevention
… among Korean patients with atrial fibrillation: The KORean Atrial Fibrillation Investigation. …

… of dabigatran therapy that resolved LV thrombus in a patients … anticoagulation, we started
dabigatran 110 mg twice daily … conducted after 7 days of dabigatran treatment, LV thrombus …

… MB/ICH in Korean patients with NVAF treated with NOACs (dabigatran/rivaroxaban/apixaban)
and those treated with warfarin, based on Korea’s nationwide insurance claims database. …

… or DOACs for stroke prevention in AF patients if the CHA2DS2-VASc score is ≥ 1 but not 2.
Dabigatran was the first DOAC approved for stroke prevention in Korea in 2009, followed by …

… involving 49 sites across 5 countries in South East Asia and South Korea where 934
patients newly diagnosed with NVAF were initiated on either dabigatran (N=591) or VKA (N=343). …

… anticoagulant–naive patients (n=23 262), dabigatran and apixaban … Korean patients are
enrolled showed that the therapeutic range of international normalized ratio is lower in Korean …